Prime Medicine Stock (NASDAQ:PRME)

Forecast Revenue Ownership Financials Chart

Previous Close

$3.84

52W Range

$1.11 - $6.94

50D Avg

$3.69

200D Avg

$4.09

Market Cap

$668.04M

Avg Vol (3M)

$2.54M

Beta

2.67

Div Yield

-

PRME Company Profile

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

214

IPO Date

Oct 20, 2022

Website

PRME Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24
Reportable Segment	$4.63M	$2.98M

Fiscal year ends in Dec 25 | Currency in USD

PRME Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$4.63M	$2.98M	-
Operating Income	$-208.35M	$-202.47M	$-204.79M
Net Income	$-201.14M	$-195.88M	$-198.13M
EBITDA	$-195.76M	$-196.34M	$-186.64M
Basic EPS	$-1.35	$-1.65	$-2.18
Diluted EPS	$-1.35	$-1.65	$-2.18

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
EYPT	EyePoint Pharmaceuticals, Inc.
VIR	Vir Biotechnology, Inc.
SEPN	Septerna, Inc.
KURA	Kura Oncology, Inc.
BCAX	Bicara Therapeutics Inc. Common Stock
RZLT	Rezolute, Inc.
TYRA	Tyra Biosciences, Inc.
REPL	Replimune Group, Inc.
MRVI	Maravai LifeSciences Holdings, Inc.
PROK	ProKidney Corp.